Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Food and Drug Administration

NRx Pharmaceuticals
Regional

FDA Fast Track Puts Ketamine-Based Therapy in Spotlight for Suicide Care

January 22, 2026January 20, 2026 - by Timothy Alexander

WILMINGTON, DE — NRx Pharmaceuticals, Inc. said it has secured Fast Track designation from the U.S. Food and Drug Administration for NRX-100, a preservative-free ketamine formulation aimed at treating suicidal …

FDA Fast Track Puts Ketamine-Based Therapy in Spotlight for Suicide Care Read More

Cabaletta Bio
Regional

Cabaletta Targets 2027 FDA Filing as Autoimmune CAR-T Push Accelerates

January 20, 2026January 19, 2026 - by Timothy Alexander

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) laid out an ambitious 2026 roadmap centered on advancing rese-cel, its experimental CAR T cell therapy for autoimmune diseases, as the company …

Cabaletta Targets 2027 FDA Filing as Autoimmune CAR-T Push Accelerates Read More
Food and Drug Administration
Health / Medical / National

FDA Clears Faster Path for Gene Cures as Rare Disease Breakthrough Arrives

January 18, 2026January 18, 2026 - by Maryann Pugh

WASHINGTON, D.C. — The U.S. Food and Drug Administration signaled a sweeping shift in how cutting-edge therapies reach patients this month, unveiling regulatory flexibility for cell and gene therapies, modernizing …

FDA Clears Faster Path for Gene Cures as Rare Disease Breakthrough Arrives Read More

iECURE
Regional

FDA Fast-Track Boost Lifts iECURE Gene Therapy Toward Hope for Newborns

January 18, 2026January 17, 2026 - by Timothy Alexander

PHILADELPHIA, PA — A rare-disease gene therapy developed in Philadelphia has cleared a major regulatory hurdle, positioning it on an accelerated path toward approval in the United States and the …

FDA Fast-Track Boost Lifts iECURE Gene Therapy Toward Hope for Newborns Read More
Cosmetics
Health / Medical / National

FDA Finds Widespread PFAS in Cosmetics but Says Safety Data Falls Short

January 4, 2026January 3, 2026 - by Maryann Pugh

WASHINGTON, D.C. — The Food and Drug Administration has released a congressionally mandated review of perfluoroalkyl and polyfluoroalkyl substances in cosmetic products, concluding that scientific evidence is too limited to …

FDA Finds Widespread PFAS in Cosmetics but Says Safety Data Falls Short Read More

INOVIO Pharmaceuticals
Regional

FDA Sets 2026 Decision Clock for INOVIO’s Rare Disease Therapy

January 3, 2026January 3, 2026 - by Timothy Alexander

PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) said the U.S. Food and Drug Administration has accepted its Biologics License Application for INO-3107, a potential non-surgical treatment for adults with recurrent …

FDA Sets 2026 Decision Clock for INOVIO’s Rare Disease Therapy Read More
Savara
Regional

FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease

December 31, 2025December 30, 2025 - by Timothy Alexander

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it has resubmitted its biologics license application for MOLBREEVI to the U.S. Food and Drug Administration, a key regulatory step toward approval …

FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease Read More

AstraZeneca
Regional

ENHERTU Scores Tenth FDA Fast-Track as Breast Cancer Data Shifts Playbook

December 31, 2025December 30, 2025 - by Timothy Alexander

WILMINGTON, DE — AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) said their jointly developed breast cancer therapy ENHERTU has received Breakthrough Therapy Designation from the U.S. Food and Drug …

ENHERTU Scores Tenth FDA Fast-Track as Breast Cancer Data Shifts Playbook Read More
Court News
Crime & Safety / National

Fake “Smart Chip” Cancer Scans Unraveled in Federal Fraud Guilty Pleas

December 30, 2025December 30, 2025 - by Zainuddin Harinder

PHILADELPHIA, PA — A husband-and-wife operation that claimed it could diagnose and cure cancer using so-called “smart chip technology” embedded in ultrasound machines has collapsed after both principals pleaded guilty …

Fake “Smart Chip” Cancer Scans Unraveled in Federal Fraud Guilty Pleas Read More
GSK plc
Regional

FDA Clears GSK’s Twice-Yearly Asthma Drug, Signaling Shift in Biologic Care

December 28, 2025December 27, 2025 - by Timothy Alexander

PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) said the U.S. Food and Drug Administration has approved Exdensur, a twice-yearly biologic treatment for patients with severe asthma characterized by an eosinophilic …

FDA Clears GSK’s Twice-Yearly Asthma Drug, Signaling Shift in Biologic Care Read More

Posts pagination

Previous 1 … 5 6 7 … 35 Next

Trending News

  • Six Charged in Street Racing Crackdown After Months Probe

  • $20K Reward as Homicide Suspect Sought in Mass Shooting

  • Warrant Issued as Stalking Suspect Vanishes in Parkesburg

  • Brewers Sound Alarm as Closures Mount Across Pennsylvania

  • Cash Grab Shocks Downtown Shop, Suspects Still at Large

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Police News

Six Charged in Street Racing Crackdown After Months Probe

1 hour ago19 hours ago

Naseem Sills

$20K Reward as Homicide Suspect Sought in Mass Shooting

3 hours ago19 hours ago

William Wayne Burns

Warrant Issued as Stalking Suspect Vanishes in Parkesburg

5 hours ago20 hours ago

Copyright © 2026 MyChesCo.